Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avasopasem in Metastatic HR+ Breast Cancer
NCT07137871Phase 1Recruiting
- Sponsor
- UT Health San Antonio
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of avasopasem manganese in breast cancer, sponsored by UT Health San Antonio. Primary endpoint: Safety and Tolerability at 4 months. Started Oct 2025; status: recruiting.
02
Drugs
avasopasem manganese
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07137871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07137871.